Stock Down with Good News ? Follow the Lemmings
Motley has its Fools, digitalwrks has its Lemmings (follow me…..). digitalwrks got a small taste of NBEV stock earlier in the day…..
LOS ANGELES — President Donald Trump returned Friday to one of the most hostile political territories for him in the U.S.— California.
After a stop at the U.S. border with Mexico in Calexico, California, Trump arrived in Los Angeles to attend a fundraiser in a state where his job-approval ratings have been dismal and his past visits have been met by protesters. This time around, a few protesters held up a sign saying “Trump-Pence must go” as the president’s motorcade drove nearby on Sunset Boulevard on the way to a Beverly Hills mansion.
Trump was also expected to make an unannounced side trip to the coastal city of Rancho Palos Verdes for a dinner at his Trump golf course overlooking the Pacific Ocean with a group that included members of the City Council, the Los Angeles Times reported.
His visit came as the president was once again redefining his immigration policies, which have been widely criticized as unnecessarily cruel by many California leaders with close economic or cultural ties to nearby Mexico. Trump backed off Thursday from his latest threat to close the U.S.-Mexico border in the face of an immigration surge.
Steel said among the party’s goals is winning back the four congressional seats it lost in November in the traditional GOP stronghold of Orange County, just south of Los Angeles.
But it won’t be easy. Polls show Trump remains deeply unpopular in California. A Quinnipiac University poll released in February showed only a 28% job-approval rating across the state for Trump. Having won seven seats in the midterm election, Democrats hold a 46 to seven advantage in congressional seats from California.
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.18, marking a +1.32% move from the previous day. This change outpaced the S&P 500’s 1.16% gain on the day. Meanwhile, the Dow gained 1.27%, and the Nasdaq, a tech-heavy index, added 1.29%.
Heading into today, shares of the company had gained 19.84% over the past month, outpacing the Medical sector’s gain of 1.35% and the S&P 500’s gain of 1.92% in that time.
Aurora shows its current production capacity at 120,000 kg/year, but then has a staggering mid-2020 production capacity of 500,000+ kg/year, which is agreed upon by this article published by Forbes. That is over four times growth in just over a year, so it may not seem feasible now, but the additions of the Aurora Sun and Aurora Nordic 2 facilities should help the company accomplish these goals.
Both these facilities are over 1,000,000 square feet and some of the largest that Aurora will have in its fleet of nine others. The two additions, plus advanced cultivating techniques, include a process that can affect every variable including accurately controlling the nutrients, lighting, humidity, temp, and air flow to yield the most from every harvest. According to an article by The Motley Fool, it believes that Aurora can produce over 700,000 kg/year by mid-2020, which would be over 8.5 times growth. Aurora has a long tradition of increasing production with increased demand, so if the market demand, so if the market demanded 700,000 kg of marijuana, I believe Aurora could provide that.
New Jersey delays vote on legal weed
New Jersey lawmakers have canceled their planned vote on Monday, April 1, on legalizing the recreational use of marijuana for adults at least 21 years old. Backers say they have yet to garner enough support in the state Senate for the measure. The vote may be rescheduled for May.
Selected tickers: Cronos Group (CRON -5.5%), Canopy Growth (CGC-0.8%), Tilray (TLRY -0.8%), Aurora Cannabis (ACB -0.6%), Medical Marijuana (OTCPK:MJNA -2.5%), Cannabis Science (OTCPK:CBIS -0.5%), Alternative Harvest ETF (MJ +0.3%), Global X Fertilizer/Potash ETF (SOIL+0.1%), AdvisorShares Vice ETF (ACT +0.8%)
Therapies for Acute Pain
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.
Sufentanil is an opioid analgesic currently marketed for IV and epidural anesthesia and analgesia; however, its postoperative use has been limited due to its short duration of action when delivered intravenously.
The pharmaceutical attributes of sufentanil, including lipid solubility and degree of non-ionization, result in rapid cell membrane penetration allowing entry into the central nervous system (CNS).2 In addition, its pharmacokinetic profile when delivered sublingually could potentially avoid the high peak plasma levels and short duration of action observed with IV administration.3 Sufentanil has been shown to be 5- to 10-fold more potent than fentanyl
The Pfizer Connection
Sulopenem and Iterum
Iterum’s major achievements are three-fold;
- Recognizing and rescuing a shelved experimental medicine, with significant potential value against multi-drug resistant infections.
- Overcoming scientific and technical challenges to manufacture and deliver this compound as an antibiotic available in oral and IV forms.
- Managing an efficient, fast-moving development program that recognizes urgent medical need.
Sulopenem was discovered in the laboratories of Pfizer Inc. in the 1980s and was first developed with an intravenous (IV) formulation only. The company completed an extensive pre-clinical program, followed by human studies. Later, an oral formulation was developed and tested in Phase 1 and Phase 2 trials.
Although the results were encouraging, development of sulopenem was abandoned when Pfizer shifted focus towards other therapeutic areas.
In November 2015, Iterum successfully negotiated the license of sulopenem and its prodrugs and restarted the development program. The company is now planning its Phase 3 program.
Sulopenem is the first oral and IV penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative infections in both the hospital and community settings
HEXO Corp’s trusted medical cannabis brand
Initially incorporated in 2013 under the name Hydropothecary, the company was solely created to meet the needs of the medical cannabis market. With the advent of a legalized market, the company became HEXO Corp, retaining Hydropothecary for medical clients and creating HEXO for the adult-use community.
One of the country’s lowest-cost producers, HEXO Corp currently has more than 310,000 sq. ft. of production capacity, with another 1,000,000 sq. ft. facility now under construction.
As a leading cannabis producer, we also believe in our corporate social responsibility and how our operations impact the natural and social environment on a local, provincial and national level.
Reports Fourth Quarter and Full Year 2018 Financial Results
DUBLIN, Ireland and CHICAGO, March 25, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, today reported financial results for the fourth quarter and year ended December 31, 2018.
“We made tremendous progress in 2018. We raised over $80 million in an IPO to fund three Phase 3 trials in three indications of our lead asset, sulopenem, which were initiated in the third quarter,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics plc. “In 2019, we remain focused on completing all three trials, delivering top-line results, and preparing our New Drug Applications for submission to the U.S. Food and Drug Administration (FDA).”
250 SKUs ~ Curaleaf is known for premium, medical-grade cannabis products, and offers over 150 strains and 100 formulated products in different concentrations.
Consistency of Product ~ Products are formulated and tested to ensure that each dose has a standardized amount of cannabinoids to ensure consistent product delivery and experience
Multiple Formats ~ Multiple product formats provide an array of administration options (inhalation, ingestion, sublingual, topical) for the novice to the experiences user
Zynerba Pharmaceuticals (ZYNE) ~ (Market Cap: $124.134M; Share Price: $5.89) ~ 5 Day Chart
The leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the fourth quarter and year ended December 31, 2018 and provided an overview of recent operational highlights. Armando Anido, Chairman and Chief Executive Officer of Zynerba, commented on the results, “the fourth quarter of 2018 was a period of strong clinical and corporate momentum, as we achieved our remaining 2018 milestones and positioned ourselves well for a watershed year in 2019.
We continued enrollment into CONNECT-FX, our pivotal trial of Zygel™ in Fragile X Syndrome, and completed enrollment in BELIEVE 1, our Phase 2 trial in Developmental and Epileptic Encephalopathies. We also initiated the BRIGHT trial, which will evaluate Zygel in Autism Spectrum Disorder and are on track to initiate a Phase 2 trial in 22q11.2 Deletion Syndrome in the second quarter of 2019.”